Description of rapamycin-resistance in some cancer cell line (e.g. rhabdomyosarcoma Rh30) is reported[47], [48], thus identification of disconnected circuit in TORC1 signaling which confers rapamycin-insensitivity should be quite informative for application of rapamycin as an anti-cancer drug. The gene discussed is CRTC1; the disease is cancer.